title: PRAMEing a picture of differentiation therapy for AML?
abstract: Addition of retinoic acid to chemotherapy improves survival of patients with acute myeloid leukemia. This effect is more pronounced in leukemias that express high levels of PRAME. PRAME is an inhibitor of retinoic acid signaling, which may prove to be an important marker for retinoic acid response.
authors.affiliation: University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA. redner@pitt.edu
authors.forename: Robert L
authors.initials: RL
authors.lastname: Redner
mesh_terms: D000951:Antigens, Neoplasm / Q000502:physiology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002454:Cell Differentiation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D018168:Receptors, Retinoic Acid / Q000378:metabolism*; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D000951:Antigens, Neoplasm; C404944:PRAME protein, human; D018168:Receptors, Retinoic Acid; D014212:Tretinoin